Molecular epidemiology and genetic diversity of human metapneumovirus among hospitalized children in Saudi Arabia during the COVID-19 era Authors: Abdulaziz M Almuqrin, Ibrahim M Aziz, Abdulrahman F Alrezaihi, Lama Alzamil, Mohamed A Farrag, Taghreed A Hafiz, Reem M Aljowaie, Fahad N Almajhdi Published: 2025 ABSTRACT AbstractIntroductionHuman metapneumovirus (HMPV) is a major viral cause of acute respiratory tract infections, especially in young children and older adults. However, data on its molecular epidemiology in the Middle East remain scarce. As the COVID-19 pandemic may have altered the circulation and molecular epidemiology of respiratory viruses, this study represents one of the first efforts to assess the genetic diversity and circulation patterns of HMPV in Saudi Arabia during the COVID-19 era.MethodsA total of 216 nasopharyngeal aspirates were collected from hospitalized children with suspected respiratory infections in Riyadh during the COVID-19 pandemic. Samples were screened for HMPV by RT-PCR, and the full-length G gene of positive isolates was amplified, sequenced, and analyzed for phylogeny, mutations, and glycosylation profiles.ResultsHMPV was detected in 10 (4.63%) of screened samples, with the highest prevalence among children aged 2–5 months and a predominance in males. Co-infections with other respiratory viruses were observed in 5 (50%) positive cases. Phylogenetic analysis identified five distinct genotypes (A2.1, A2.2, A2.2.2, B1, B2). Notably, genotype A2.2.2 was identified for the first time in Saudi Arabia and the Middle East region. Comparative sequence analysis revealed 43.75% nucleotide mutations and 25.83% amino acid substitutions, many of which were genotype-specific, along with distinct glycosylation patterns unique to the study isolates.ConclusionThis study provides the first molecular characterization of HMPV in Saudi Arabia during the COVID-19 pandemic. The results demonstrate notable genetic diversity, including the circulation of five genotypes and the first detection of the A2.2.2 genotype in the country. These findings highlight the importance of continuous genomic surveillance to monitor viral evolution and guide regional public-health strategies.Clinical trial numberNot applicable.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-025-12080-1.Keywords: Epidemiology, Respiratory viruses, Human metapneumovirus, Sequence and phylogenetic analysis Introduction Acute respiratory tract infections (ARTIs) are among the leading causes of morbidity and mortality worldwide, and viruses are primarily responsible for these infections. Human metapneumovirus (HMPV) is a respiratory pathogen first identified in 2001 in the Netherlands [1], and has since been recognized as one of the major viral causes of respiratory infections [2–4]. Although HMPV usually results in mild to self-limiting infections of the respiratory tract, it could cause bronchiolitis and severe pneumonia, especially in immunocompromised patients, young children, and older adults [5]. A study by Zhu et al. determined that HMPV was the sixth most detected virus among hospitalized children due to lower respiratory tract infections. In addition, that study identified HMPV as the third most prevalent virus associated with coinfections [6]. HMPV infection follows different patterns in different countries. For instance, HMPV outbreaks in Europe and North America occur mainly during winter, whereas the virus causes epidemics during the rainy seasons in some Asian countries [7, 8]. HMPV is an enveloped, single-stranded, non-segmented RNA virus with a genomic size ranging between 13,281 and 13,387 nt in length [9]. It is a member of the Metapneumovirus genus, which belongs to the Pneumoviridae family. The viral genome possesses eight genes that encode nine proteins, three of which represent surface proteins, including the attachment glycoprotein (G), the short hydrophobic protein (SH), and the fusion protein (F) [10]. The variations in surface proteins are commonly used to assess variations in viral strains [11]. Both the F and G genes are primarily used in HMPV genotyping and phylogenetic studies. While the F gene is more conserved and therefore widely employed for broader phylogenetic comparisons, the G gene is commonly used in many genotyping studies because of its high genetic and antigenic variability, particularly for fine-scale lineage discrimination [12–14]. Based on the genetic analysis of the G gene, HMPV is classified into two genotypes, A and B. Genotype B is further classified into two clades, B1 and B2. Genotype A is divided into four clades, including A1, A2.1, A2.2, and A2.2.2 [15]. It is common to observe an ongoing annual circulation of different HMPV genotypes within a specific geographic region where a single genotype is prevalent. Every one to three years, the dominant genotype shifts due to the emergence of genotype-specific immunity [16]. Because of ongoing instability and conflicts in several Middle Eastern countries, studies investigating the prevalence and molecular epidemiology of respiratory viruses, more specifically, HMPV, are scarce. As a result, newly emerging HMPV strains may be introduced and circulate within the region without being identified. Saudi Arabia is one of the major Middle Eastern countries, and it presents a unique context for respiratory virus circulation. The presence of millions of foreign workers, combined with the annual gathering of millions of people during the Hajj and Umrah seasons, creates ideal conditions for the introduction and dissemination of new viral strains [17, 18]. In Saudi Arabia, limited data show variable HMPV activity, with peaks reported between January–March and occasionally in August–September. In the neighboring United Arab Emirates, HMPV detections occurred sporadically throughout the year, which suggests that HMPV infections in the Gulf region appear year-round but are more frequent during winter and early spring [18, 19]. Moreover, it has been reported that the COVID-19 pandemic likely influenced the epidemiology and molecular evolution of respiratory viruses through factors such as public health interventions, reduced human mobility, and shifts in viral dynamics [20]. While our group previously examined the molecular epidemiology of HMPV during 2008–2009 [21], such investigations have remained scarce in Saudi Arabia and across the Middle East region. Given the scarcity of molecular data on circulating HMPV strains in the Middle East following the COVID-19 pandemic, this study provides new evidence on HMPV diversity and transmission dynamics, offering important insights to guide future research and public health strategies in Saudi Arabia and the Middle Eastern region. Materials and methods Sample collection Following the approval of the King Saud University Institutional Review Board Ethics Committee in Riyadh, Saudi Arabia (Ethics Reference No. E-141326/IRB), and after obtaining written informed consent from the parents or legal guardians of all child participants, a total of 216 nasopharyngeal aspirate (NPA) samples were collected from hospitalized children experiencing acute respiratory symptoms such as cough, fever, breathing difficulty, and runny nose at King Khalid University Hospital during the winter season (December–March) of 2020/2021. The collected samples were mixed with 2 mL of the virus transport medium and immediately transported in cooling boxes into the Virology Research Laboratory (VRG), College of Science, King Saud University. Samples were then aliquoted and stored at − 80 °C until the day of analysis. HMPV screening and sequencing Using the QIAamp viral RNA extraction kit (Qiagen, Hilden, Germany), viral RNA was isolated from NPA samples following the manufacturer’s instructions. The extracted genomic material was used to screen the samples for the presence of HMPV using a One-Step Ahead RT-PCR Kit with Taq High Fidelity DNA Polymerase (Qiagen, Hilden, Germany). Moreover, positive HMPV samples were tested for possible co-infections with other common pediatric respiratory viruses (such as RSV and rhinovirus) via single-virus RT-PCR assays, which were based on their high prevalence in the region; screening did not involve SARS-CoV-2 since all the study samples were confirmed negative by the routine hospital PCR test before being taken, and parainfluenza viruses were excluded due to their lower incidence in the similar cohorts during the study period. The amplification reaction was performed in a Gene-Amp 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA). Amplification and sequencing of the complete G gene The full-length G gene of all the positive samples was amplified using a One-Step Ahead RT-PCR Kit with Taq High Fidelity DNA Polymerase (Qiagen, Hilden, Germany) according to the kit’s guidelines. The PCR reaction was performed in the Gene Amp 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA) with the primer SH7(+): 5′-TACAAAACAAGAAMATGGGACAAG-3′ and SH-8(–):5′ -GAGATAGACATTAACAGTGGATT-3 ′. The reaction was carried out using the following cycling conditions: reverse transcription at 50º C for 30 min; initial denaturation at 95º C for 15 min, followed by 45 cycles of denaturation at 94º C for 30 s, annealing at 52º C for 30 s, and extension at 72º C for 2 min; and a final extension step of 72º C for 10 min. The PCR products were visualized on a 1% ethidium bromide-stained agarose gel, and size was discriminated using a 100 bp Plus DNA ladder (Qiagen, Hilden, Germany). The amplified fragments of the G gene were sequenced in both directions at Macrogen Inc (Macrogen, Seoul, South Korea). The final assembled sequences were added to the GenBank database with accession numbers [PP786283- PP786293). Sequence and phylogenetic analysis The generated raw DNA sequence data were trimmed and aligned with local and international HMPV strains (n = 52) obtained from the GenBank databases (Supplementary Table S1), utilizing the Bioedit program, version 7.2.5 (Ibis Biosciences, Carlsbad, CA, USA). The strain NC 039199.1 HMPV/00–1/RF was set as a reference sequence. To track the evolution of Saudi HMPV isolates in Riyadh, multiple sequences were aligned at both the nucleotide and deduced amino acid levels using Clustal W, implemented in the MegAlign program of Lasergene software, version 3.18 (DNAStar, Madison, WI). Divergence analysis, identification of mutation sites, and prediction of amino acid changes were carried out using EditSeq and MegAlign programs, and Lasergene software (DNAStar Inc., Madison, WI). The prediction of potential N-and O‐linked glycosylation sites in G-protein of HMPV isolates was assessed using Net‐N‐glyc 1.0 (https://services.healthtech.dtu.dk/services/NetNGlyc-1.0/) and Net‐O‐glyc 3.1 (https://services.healthtech.dtu.dk/services/NetOGlyc-4.0/), respectively. A phylogenetic analysis was conducted based on the G gene using the neighbor-joining method (MEGA v11.0 software). Bootstrap values above 60% were labeled on major tree branches for reference, and 1000 bootstrap replications were used. Statistical analysis Statistical analyses were performed using SPSS (version 28.01; IBM, Armonk, NY, USA), and a significant level was discovered. Data were displayed as numbers or percentages (%). The “P” value > 0.05 was employed to evaluate statistical significance. Results HMPV epidemiology and prevalence A total of 216 NPA samples from hospitalized children (aged 0 to 5 years) due to RTIs were screened for HMPV utilizing RT-PCR. As shown in Table 1, the HMPV was detected in 10 cases, representing 4.63% of the samples screened. The age-based analysis revealed that the prevalence of HMPV was significantly higher (P = 0.037) in the 2-5-month age group compared to the other age groups (< 2 months, 6–11 months, and ≥ 12 months). A gender-based comparison showed that HMPV infections were more common in males (P = 0.012), accounting for 70% of positive cases. In addition, half of the HMPV-positive samples were co-infected with other respiratory viruses, including two samples with HRSV and three cases with rhinoviruses. However, the absolute number of HMPV-positive cases was relatively small, which may affect the statistical power of comparisons across demographic groups. A visual overview of the screening process and the distribution of co-infections is illustrated in Fig. 1. Table 1The demographic characteristics of the HMPV-infected children, the prevalence of HMPV, and viruses co-infected with HMPVSeasonal and demographic detailsNumber of samplesNumber of positive samples (%) Year 20201125(4.44)20211045 (4.81)Total21610 (4.63) Age in years < 2 months332 (6.06)2–5 months32 4 (12.50) * 6–11 months783 (3.85)≥ 12 months731 (1.37) Gender Male127 7 (5.51) * Female893 (3.37) Co-infection HRSV2 (2)Rhinovirus3 (3)Data were displayed as numbers or percentages (%). Statistically significant values were labeled with *= (P < 0.05) The demographic characteristics of the HMPV-infected children, the prevalence of HMPV, and viruses co-infected with HMPV Data were displayed as numbers or percentages (%). Statistically significant values were labeled with *= (P < 0.05) Flow chart of the screened samples for HMPV. Positive samples were further screened for co-infections with multiple respiratory viruses Circulation pattern of HMPV genotypes and sub-genotypes As shown in Fig. 2, the analysis of the HMPV G gene sequences revealed that the study isolates clustered into five distinct genotypes. A2.2 and B1 were the most prevalent genotypes, as six isolates (60%) were evenly grouped under them. Two isolates were grouped under the B2 (20%) genotype, while one isolate each (10%) was classified as A2.1 and A2.2.2, respectively. The phylogenetic tree is based on the full-length G gene of the HMPV isolates in 2020–2021. The name, accession numbers, and genotype of reference strains used to generate the phylogenetic tree are shown. The Clustal W was utilized to perform multiple sequence alignment, and the tree was constructed by the MEGA v11.0 program using the neighbor-joining method with bootstrap values of 1,000 replicates. The bootstrap values exceeding 60% were only shown. The HMPV isolates identified in the 2008–2009 study are labeled in blue, while those identified in the current study are labeled in red. The outer line of the phylogram denotes the HMPV genotypes The analysis showed that the Riyadh HMPV isolates belonging to the B1 and B2 genotypes were predominant during 2020 and circulated at a comparable rate. Importantly, and as noted earlier, one isolate was classified within subgroup A2.2.2. To our knowledge, this represents the first detection and emergence of the A2.2.2 genotype in Saudi Arabia and the Middle Eastern region. On the other hand, the predominant HPMV isolates identified in 2021 were grouped in the A2.2 genotype (30%). Two isolates were divided between A2.1 (10%) and B1 (10%) genotypes, respectively. The analysis indicated that HPMV A2.1 and B1 genotypes were cocirculated at a similar rate. Analysis of nucleotide sequences and deduced amino acids The G gene sequences of the study HMPV isolates circulating in 2008–2009 in Saudi Arabia and 2020–2021 in the current study were compared to 52 G sequences representing several HMPV genotypes from different countries worldwide. The analysis of the G nucleotide sequences identified 315/720 mutation sites (43.75%) in all study HMPV strains of every genotype. The results showed that 186 nucleotide substitutions (25.83%) have led to changes in the corresponding amino acid residues. The mutations, including 77 A, 83Y, 98 F, 117 S, 140 N, 146 L, 156T, 160 S, 170 W, and 221 H, were identified as being specific amino acid mutations for the A2.1 genotype in the study HMPV isolates (Table 2). The analysis showed that amino acid substitutions including 102 F, 110 V, 122 g, 156I, 158I, 178P, 182 V, 183 F, 227E were specific for genotype A2.2. In addition, the amino acid mutations, including 26R, 57R, 62T, 66 A, 70 S, 71 A, 68 S, 97 W, 101 N, 11D,114Y, 119Q, 125 A,126P, 132 K, 135 A, 138 K, 140T, 142E, 144I, 155R, 159Q,161R, 162 K, 164G, 169 N,170Q, 223I, 224 K, 226 A, 227 S, 230I, 234D, 239D, and 250R were observed in the studied HMPV genotype B1. Furthermore, the results showed that HMPV isolates in the B2 genotype contained the amino acid substitutions including 60T, 66 V, 76 K, 82 A, 84D, 86 N, 89 L, 101D, 111 N, 114 H, 119P, 123 A, 132E, 137 L,138R, 140I, 142R, 155G, 161 K, 162E, 1664E, 169T, 180 L, 223T, 227R, 238 N, 234G, 249I, and 250Q. Table 2Amino acid changes among strains of the HMPV genotypes, yellow rectal refers to the difference in amino acids from the reference strainGenotypeMutation Site2657596062646668707176778283848689939798101102110111112114117HMPV/00–1KKTSSHTS P METTD N DSHQSGSASSE P A.2.1Riyadh 31/2021...........AIY..P..FNP..P.SRiyadh 131/2009...........AIY..P..FNP..P.SA.2.2Riyadh 34/2021............I..GP..PSFV.P..Riyadh39/2021............I...P...SFV.P..Riyadh 77/2021............I..GP..PSFV.P..Riyadh 113/2009............I..GP..PSFV.P.._Riyadh134/2009............I..GP..PSFV.P..Riyadh 174/2009............I...P...SFV.P..A2.2.2Riyadh 14/2020..AF...F....I...TL..SP..P..B1Riyadh 44/2020RRMITNAMSA...ASSPQWTN.EDHYTRiyadh 56/2020RRMITNAMSA...ASSPQWTN.EDHYTRiyadh 72/2021RRMITNAMSA...AGSPQWTN.EDHYTRiyadh 16/2008RRMITNAMSA...ASSPQWTN.EDHYTRiyadh 34/2008RRMITNAMSA...ASSPQWTN.EDHYTRiyadh 40/2008RRMITNAMSA...AGSPQWTN.EDHYTB2Riyadh 17/2020..MTV.VM.VK.AADNLQSTD.ENHHTRiyadh 53/2020..MTV.VM.VK.AVDNLQLTD.ENHHTRiyadh 117/2009..MTV.VM.VK.AADNLQSTD.ENHHTRiyadh 153/2009..MTV.VM.VK.AVDNLQLTD.ENHHT Genotype Mutation Site 119 122 123 125 126 132 135 137 138 140 142 144 146 155 156 158 159 160 161 162 164 169 170 HMPV/00–1 S D T N R T T P S S T T P Q G S S R T H . P R A.2.1Riyadh 31/2021...D.R...N..L.TASS.Q..WRiyadh 131/2009.....R...N..L.TASS.Q..WA.2.2Riyadh 34/2021.G.D.R......S.IIS..Q.S.Riyadh39/2021.GID.R......S.IIS..Q...Riyadh 77/2021.G.D.R......S.IIS..Q.S.Riyadh 113/2009.G...R......S.IIS..Q.S._Riyadh134/2009.G...R......S.IIS..Q.S.Riyadh 174/2009.GI..R......S.IIS..Q...A2.2.2Riyadh 14/2020.....R......S.AAS..Q.S.B1Riyadh 44/2020Q..APKA.KTEIQRATQKRKGNQRiyadh 56/2020Q..APKA.KTEIQRATQKRKGNQRiyadh 72/2021Q..APKA.KTEIQRATQKRKGNQRiyadh 16/2008Q..APKA.KTEIQRATQKRKGNQRiyadh 34/2008Q..APKA.KTEIQRATQKRKGNQRiyadh 40/2008Q..APKA.KTEIQRATQKRKGNQB2Riyadh 17/2020P.AVSE.LRIR.QGAT.KKEET.Riyadh 53/2020P.AVSE.LRIR.QGAT.KKEET.Riyadh 117/2009P.AISE.LRIR.QGAT.KKEET.Riyadh 153/2009P.AISE.LRIR.QGAT.KKEET. Genotype Mutation Site 180 182 183 221 222 223 224 225 226 227 230 234 238 239 244 249 250 HMPV/00–1 T T L R T S S T R K S V I S K S P A.2.1Riyadh 31/2021A..HM...G.T.S.NGSRiyadh 131/2009A..HM...G.T.S.NGSA.2.2Riyadh 34/2021.VF.....GET.S.NGSRiyadh39/2021.VF.....GET.S.NGSRiyadh 77/2021.VF.....GET.S.NGSRiyadh 113/2009.VF.....GET.S.NGSRiyadh134/2009.VF.....GET.S.NGSRiyadh 174/2009.VF.....GET.S.NGSA2.2.2Riyadh 14/2020A......S.GT.S.NGSB1Riyadh 44/2020..TNQIRNASID.DITRRiyadh 56/2020..TNQIRNASID.DITRRiyadh 72/2021..TNQIRNASID.DITRRiyadh 16/2008..TNQIRNASID.DITRRiyadh 34/2008..TNQIRNASID.DITRRiyadh 40/2008..TNQIRNASID.DITRB2Riyadh 17/2020L.TNQT.NGRTANGNIQRiyadh 53/2020L.TNQT.NGRTANGNIQRiyadh 117/2009L.TNQT.NGRTANGNIQRiyadh 153/2009L.TNQT.NGRTANGNIQ Amino acid changes among strains of the HMPV genotypes, yellow rectal refers to the difference in amino acids from the reference strain Glycosylation profiles of the Riyadh HMPV isolates The N- and O-linked glycosylation sites in the G proteins of the study HMPV isolates were analyzed and compared to various international HMPV strains from different genotypes. The analysis showed that the number of O-linked glycosylation sites in the study HMPV isolates ranged from 15 to 20, which exhibited a high degree of conservation across the HMPV genotypes. In addition, we identified an amino acid substitution (S140N) that introduced a novel potential N-glycosylation site at position 140 (NRT) in the Riyadh 31/2021 isolate. Interestingly, this same substitution was also observed in the Riyadh 131/2009 sample, and it appeared to be unique to Riyadh HMPV isolates. Moreover, all Riyadh isolates carried an additional putative N-glycosylation site at position 145 (NST), representing a distinct glycosylation pattern not seen in other reference sequences. Furthermore, a K151N substitution in the Riyadh 44/2020 isolate gave rise to an extra potential N-glycosylation site, further highlighting the unique molecular signature of these isolates. The amino acid substitution P169N was also identified, giving rise to an additional potential N-glycosylation site in six isolates (Riyadh 44/2020, Riyadh 56/2020, Riyadh 72/2021, Riyadh 16/2008, Riyadh 34/2008, and Riyadh 40/2008). This mutation was unique to the B1 genotype. A similar finding was made in the (T225N) amino acid change, which resulted in an extra and unique possible N-glycosylation site (NAS). In contrast, the R221N substitution was observed exclusively in Riyadh B2 genotype strains, further distinguishing these isolates at the molecular level (Fig. 3). Deduced amino acid alignments of complete G genes of the study, local and international HMPV strains. Several international HMPV strains from various genotypes were selected and aligned against the Riyadh HMPV isolates using the Clustal W technique within the MegAlign program (DNAstar). The alignments are displayed in comparison with the reference sequences of the original HMPV, identified by the accession number NC 039199.1. The identical amino acid residues are represented by dots. The predicted O-glycosylation sites in the original strain are labeled with filled circles Discussion HMPV infection was first identified in 2001 from a group of children with respiratory tract infections in the Netherlands [1]. Since then, HMPV has become one of the leading causes of ARTI worldwide. HMPV infection occurs across all age groups, but is most common in infants and young children, who tend to experience more severe disease due to their developing immune systems [22, 23]. Despite this global significance, molecular data on circulating HMPV strains remain scarce in the Middle East region, especially in the COVID-19 period [24, 25]. The present study is the first to fill this gap by investigating the genetic diversity of circulating HMPV strains in one of the major Middle Eastern countries during the COVID-19 era. This study reported a prevalence of 4.63% for HMPV infection among children with ARTI, with most cases occurring in males. The incidence was highest among children aged 2–5 months. The prevalence of HMPV infection observed in this study is comparable to the HMPV incident rates reported in Kuwait [26], Egypt [27], Sudan [28], and Bulgaria [29] but lower than the prevalence rates documented in Norway (9.4%), Italy (9.3%), and the United States (6%) [30–32]. Several studies reported lower HMPV incident rates than what we reported in this study, including China (1.7%) [33] and Cambodia (1.7%) [34]. The variations in the HMPV incident rate between this study and the others could be attributed to differences in the sample sizes, study duration, screening techniques, and countries’ economic levels [3]. Interestingly, an investigation conducted by our group in the pre-COVID-19 era, in 2008–2009, showed that the prevalence of HMPV was 10.9%, which is substantially higher than what is reported by the present study [21]. The disparity in the HMPV incident rates between the two studies may have resulted from the timing of the sample collection, as the current study was conducted in the COVID-19 period. The pandemic has significantly altered the epidemiology of respiratory viruses, including influenza, HRSV, HMPV, and other viruses with seasonal patterns [35–38]. It is well-established that COVID-19 mitigation measures, such as mask-wearing, social distancing, enhanced hygiene practices, school closures, and travel restrictions, led to a marked reduction in the incidence of respiratory viral infections during this period [39, 40]. Co-infections involving HMPV and other respiratory pathogens are frequently reported, and previous studies have demonstrated that such co-infections may exacerbate disease severity and increase hospitalization rates [41, 42]. In the present study, co-infections with other respiratory viruses were observed in 50% of HMPV-positive cases, primarily with HRSV and rhinovirus. This proportion was higher than that reported in other studies in Egypt (4.3%) [25], Bulgaria (13.3%) [29], and China (36.5%) [43]. The elevated HMPV co-infection rate in the current study could result from the overlapping endemicity of HMPV, HRSV, and rhinovirus during the study period, which likely increased the probability of concurrent infections [44, 45]. Although the G protein has been proposed to play roles in viral attachment and suppression of the host immune response [46, 47], recent investigations indicate that HMPV G isn’t responsible for suppressing interferon responses, and that interferon induction observed in HMPV G mutant studies likely arises from defective HMPV genome rather than direct immune evasion by the G protein [48, 49]. Nevertheless, due to its high sequence variability and accumulation of genotype-specific mutations, the G gene remains a primary target for molecular epidemiological and phylogenetic analyses of HMPV. To evaluate the genetic mutations and variations of the HMPV isolates analyzed in this investigation, the study isolates were aligned and compared with international reference strains and with our previously characterized local isolates collected from the same region during 2008–2009, before the COVID-19 pandemic [21]. Consistent with earlier reports suggesting the possibility the co-circulation of multiple HMPV genotypes within a single epidemic season [50, 51], our phylogenetic analysis confirmed the presence of several genotypes, including B1, B2, A2.1, and A2.2. In addition, the results of this investigation showed that the HMPV genotypes identified during the 2008–2009 period (B1, B2, A2.1, and A2.2) continued to circulate through the COVID-19 era [21]. Notably, and for the first time, our analysis revealed the emergence of the A2.2.2. genotype during the COVID-19 period. To our knowledge, this genotype had not been previously reported in Saudi Arabia or elsewhere in the Middle East. The observed amino acid substitutions across the A2.1, A2.2, B1, and B2 HMPV genotypes in the current investigation were generally consistent with those reported in our previous study, supporting that the G gene exhibits genotype-specific variability and can serve as a reliable molecular marker for tracking viral evolution and lineage diversity [21]. As mentioned earlier, one of the notable findings of the current study is the identification of the A2.2.2 genotype for the first time in Saudi Arabia. A2.2.2 strains carrying a 111- or 180-nucleotide duplication in the G gene were first identified in Japan [52, 53], and have since been increasingly reported in multiple countries worldwide [54–56]. However, the A2.2.2 isolate identified in the present study (Riyadh 14/2020) lacked this characteristic duplication. Similar findings have been described where both duplicated and non-duplicated A2.2.2 variants were observed to co-circulate, or where only non-duplicated strains were detected during the same epidemic seasons [55, 57]. Given that only a single A2.2.2 isolate was identified in our report, it is not possible to definitively conclude that the currently circulating A2.2.2 viruses in Riyadh represent non-duplicated variants. Additional A2.2.2 isolates are needed to confirm this observation. The present analysis revealed a considerable degree of genetic diversity among the HMPV isolates, reflected by multiple amino acid substitutions, some of which were genotype-specific. This observation is consistent with the findings of Yang et al., who concluded that HMPV G protein exhibits high intra-lineage sequence conservation but substantial inter-lineage variability [58]. Glycosylation modifies the physicochemical and biological properties of glycoproteins, influencing protein folding, conformational stability, resistance to proteolysis, and intracellular trafficking [49]. It also plays a critical role in viral infectivity and antigenicity; for instance, glycosylation can mask epitopes and thereby facilitate immune evasion [59]. In this study, several amino acid residues in the HMPV G protein were predicted to serve as potential O-linked glycosylation sites, whereas only a few N-linked sites were identified in the analyzed isolates. These results were consistent with our prior report, which showed that Saudi HMPV strains possessed 2–5 predicted N-linked sites and 60–66 predicted O-linked sites. Notably, the N-linked glycosylation pattern seems to be genotype-specific [21]. This study has several strengths. By combining epidemiological and molecular analyses, it provides novel insights into HMPV prevalence, co-infections, and genotype distribution in Saudi Arabia and the Middle East region during the COVID-19 period. However, a few limitations should be acknowledged. The small sample size used in this study may limit the ability to draw firm epidemiological conclusions. Also, the restriction of sample collection to a single healthcare facility may further limit the generalizability of the presented findings. Hence, the epidemiological observations in this study should be interpreted with caution. In addition, the lack of access to detailed clinical information for the screened patients prevents assessing the clinical characteristics associated with different HMPV genotypes. More cohort studies from various locations in Saudi Arabia and other Middle Eastern countries during successive epidemic seasons are needed to better understand the evolution and genetic diversity of the circulating HMPV strains in the region. In conclusion, this is the first study to report the genetic diversity of HMPV isolates during the COVID-19 era in one of the major Middle Eastern countries, Saudi Arabia. The prevalence of HMPV infection among hospitalized children was detected in 10 samples (4.63%); half of them were co-infected with HRSV, rhinoviruses, or both. The molecular epidemiology analysis of this study revealed that the HMPV isolates clustered into five genotypes (B1, B2, A2.1, A2.2, and A2.2.2), with A2.2 and B1 being the most common. Of particular interest, an A2.2.2 genotype was identified for the first time in Saudi Arabia and the Middle East. Given that this finding is based on a single isolate, it should be viewed as a preliminary observation that warrants confirmation through broader molecular surveillance and longitudinal studies. The G gene sequence analysis of the study HMPV isolates revealed multiple genetic variations, including glycosylation sites, point mutations, and differences in protein length. Several amino acid residues in the G protein were predicted to serve as potential O-linked glycosylation sites, whereas relatively few N-linked sites were identified, some of which appeared to be genotype-specific. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements The authors would like to extend their appreciation to the Deanship of Scientific Research at King Saud University for funding this work through Waed Program (W25-6). Author contributions Conceptualization, A.M.A. and T.H.; methodology, A.M.A and I.M.A.; software, I.M.A. and L.A; validation, A.M.A, F.N.A., and R.M.A; formal analysis, A.M.A and I.M.A.; investigation, A.M.A. A.F.A. and R.M.A; resources, F.N.A and A.M.A., data curation, A.M.M.; writing—original draft preparation, A.M.A. I.M.A. and R.M.A.; writing—review and editing, All authors.; visualization, A.M.A.; supervision, M.A.F. and T.H.; project administration, A.M.A.; funding acquisition, A.M.A. All authors have read and agreed to the published version of the manuscript. Funding This work was funded by the Deanship of Scientific Research at King Saud University through the Waed Program (W25-6). Data availability The datasets generated and analyzed during the current study are available in the GenBank repository under accession numbers PP786283–PP786293. Declarations Ethical approval The study was conducted following the Declaration of Helsinki and was approved by the King Saud University Institutional Review Board Ethics Committee in Riyadh, Saudi Arabia (Ethics Reference No. E-141326/IRB). Written informed consent to participate was obtained from the parents or legal guardians of all child participants before sample collection. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets generated and analyzed during the current study are available in the GenBank repository under accession numbers PP786283–PP786293.